Evidence map›Paper›PMID 25152601›Full record

ArticleWorld journal of gastroenterology2014

Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Antonio Rollan, Juan Pablo Arab, M Constanza Camargo, Roberto Candia, Paul Harris, Catterina Ferreccio, Charles S Rabkin, Juan Cristóbal Gana, Pablo Cortés, Rolando Herrero and 9 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05664685 (Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05664685 phase4completednot on this mapstarted 2022, after this paper: background citation

Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial

TypeinterventionalSponsorPontificia Universidad Catolica de ChileRan2022 to 2024Enrolled127ConditionsHelicobacter Pylori InfectionArmsOptimized bismuth quadruple therapy, Control
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Phenotypic and Genotypic Antibiotic Resistance Patterns inFrontiers in cellular and infection microbiology · 2020
    Article
  12. Article
  13. Annals of gastroenterology · 2017
    Article
  14. Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016
    Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Antonio RollanAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Juan Pablo ArabAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
M Constanza CamargoAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Roberto CandiaAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Paul HarrisAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Catterina FerreccioAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Charles S RabkinAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Juan Cristóbal GanaAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Pablo CortésAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Rolando HerreroAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Luisa DuránAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Apolinaria GarcíaAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Claudio ToledoAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Alberto EspinoAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Nicole LustigAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Alberto SarfatisAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Catalina FigueroaAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Javier TorresAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Arnoldo RiquelmeAntonio Rollan, Pablo Cortés, Luisa Durán, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7650568, Chile.
Universidad del Desarrollo · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo optimize diagnosis and treatment guidelines for this geographic region, a panel of gastroenterologists, epidemiologists, and basic scientists carried out a structured evaluation of available literature.

methodsRelevant questions were distributed among the experts, who generated draft statements for consideration by the entire panel. A modified three-round Delphi technique method was used to reach consensus. Critical input was also obtained from representatives of the concerned medical community. The quality of the evidence and level of recommendation supporting each statement was graded according to United States Preventive Services Task Force criteria.

resultsA group of ten experts was established. The survey included 15 open-ended questions that were distributed among the experts, who assessed the articles associated with each question. The levels of agreement achieved by the panel were 50% in the first round, 73.3% in the second round and 100% in the third round. Main consensus recommendations included: (1) when available, urea breath and stool antigen test (HpSA) should be used for non-invasive diagnosis; (2) detect and eradicate Helicobacter pylori (H. pylori) in all gastroscopy patients to decrease risk of peptic ulcer disease, prevent o retard progression in patients with preneoplastic lesions, and to prevent recurrence in patients treated for gastric cancer; (3) further investigate implementation issues and health outcomes of H. pylori eradication for primary prevention of gastric cancer in high-risk populations; (4) prescribe standard 14-d triple therapy or sequential therapy for first-line treatment; (5) routinely assess eradication success post-treatment in clinical settings; and (6) select second- and third-line therapies according to antibiotic susceptibility testing.

conclusionThese achievable steps toward better region-specific management can be expected to improve clinical health outcomes.

Indexed as

Delphi TechniqueAnti-Bacterial AgentsBacteriological TechniquesConsensusDisease ProgressionDrug Resistance, BacterialDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansLatin AmericaPeptic UlcerPractice Guidelines as TopicPrecancerous ConditionsPredictive Value of TestsProton Pump InhibitorsAnti-Bacterial AgentsProton Pump InhibitorsConsensus development conferenceDelphi techniqueHelicobacter pyloriLatin America

Identifiers

PMID25152601
PMCPMC4138478
OpenAlexW2171986297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.